Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-Paclitaxel + Nivolumab in Recurrent/Metastatic HNSCC Progressing on PD-1/PD-L1 Inhibitors
NCT04831320Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2021
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, nivolumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Washington University School of Medicine. Started Sep 2021; status: active, not recruiting.
02
Drugs
paclitaxelnivolumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04831320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04831320.